Results 41 to 50 of about 1,302,625 (339)

Mucosal vaccines — fortifying the frontiers

Nature reviews. Immunology, 2021
Mucosal vaccines offer the potential to trigger robust protective immune responses at the predominant sites of pathogen infection. In principle, the induction of adaptive immunity at mucosal sites, involving secretory antibody responses and tissue ...
E. Lavelle, Ross W. Ward
semanticscholar   +1 more source

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

npj Vaccines, 2023
Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the Wuhan-Hu-1 spike variant) protects against the Gamma and Delta
Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, Ella van Huizen, Johan Verspuij, Ana Izquierdo Gil, Ying Choi, Chenandly Daal, Aditya Perkasa, Adriaan de Wilde, Erwin Claassen, Rineke de Jong, Katrin E. Wiese, Lisette Cornelissen, Marieke van Es, Marjolein van Heerden, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Jessica Vreugdenhil, Karin Feddes - de Boer, Leacky Muchene, Jeroen Tolboom, Liesbeth Dekking, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn   +32 more
doaj   +1 more source

Viral targets for vaccines against COVID-19

Nature reviews. Immunology, 2020
Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic and to help the return to pre-pandemic normalcy. A great many vaccine candidates are being developed, several of which have completed late-stage clinical trials and ...
L. Dai, G. Gao
semanticscholar   +1 more source

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

MMWR. Morbidity and mortality weekly report, 2021
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug ...
W. Self, M. Tenforde, J. Rhoads, M. Gaglani, A. Ginde, D. Douin, Samantha M. Olson, H. Talbot, J. Casey, N. Mohr, A. Zepeski, T. McNeal, S. Ghamande, K. Gibbs, D. Files, D. Hager, A. Shehu, M. Prekker, H. Erickson, M. Gong, A. Mohamed, D. Henning, J. Steingrub, I. Peltan, Samuel M. Brown, E. Martin, A. Monto, Akram Khan, C. Hough, L. Busse, C. T. ten Lohuis, A. Duggal, Jennifer G. Wilson, A. J. Gordon, N. Qadir, Steven Y. Chang, C. Mallow, C. Rivas, H. Babcock, Jennie H. Kwon, M. Exline, N. Halasa, J. Chappell, A. Lauring, Carlos G. Grijalva, T. Rice, I. D. Jones, William B. Stubblefield, A. Baughman, K. Womack, C. Lindsell, K. Hart, Yuwei Zhu, Lisa Mills, Sandra N. Lester, M. Stumpf, Eric A. Naioti, Miwako Kobayashi, J. Verani, N. Thornburg, Manish M. Patel, N. Calhoun, Kempapura Murthy, Judy Herrick, A. McKillop, E. Hoffman, Martha Zayed, Michael E. Smith, Natalie Seattle, J. Ettlinger, E. Priest, Jennifer Thomas, A. Arroliga, M. Beeram, R. Kindle, Lori-Ann Kozikowski, Lesley De Souza, Scott Ouellette, Sherell Thornton-Thompson, Omar Mehkri, K. Ashok, Susan Gole, Alexander King, Bryan Poynter, Nicholas Stanley, Audrey Hendrickson, Ellen Maruggi, Tyler Scharber, J. Jorgensen, R. Bowers, J. King, V. Aston, Brent P. Armbruster, R. Rothman, Rahul R. Nair, J. Chen, S. Karow, E. Robart, P. Maldonado, Maryiam Khan, Preston So, Joel D. Levitt, Cynthia Perez, A. Visweswaran, J. Roque, Adreanne Rivera, L. Angeles, Trevor Frankel, Jennifer Goff, D. Huynh, Michelle P Howell, Jennifer Friedel, Michael Tozier, C. Driver, Michael Carricato, Alexandra E Foster, Paul Nassar, Laura Stout, Zita A. Sibenaller, Alicia Walter, J. Marés, Logan Olson, Bradley Clinansmith, C. Rivas, H. Gershengorn, E. McSpadden, R. Truscon, A. Kaniclides, Lara J. Thomas, Ramsay Bielak, W. Valvano, Rebecca Fong, W. Fitzsimmons, C. Blair, A. Valesano, Julie Gilbert, Christine D. Crider, Kyle A. Steinbock, Thomas C. Paulson, Layla A. Anderson, Christina Kampe, Jake Johnson, Rendie Mchenry, M. Blair, D. Conway, M. LaRose, Leigha D. Landreth, Madeline Hicks, L. Parks, Jahnavi Bongu, David W. Mcdonald, Candice Cass, Sondra M. Seiler, David Park, T. Hink, Meghan A. Wallace, C. Burnham, Olivia G. Arter   +157 more
semanticscholar   +1 more source

Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review

Vaccines, 2020
While COVID-19 continues raging worldwide, effective vaccines are highly anticipated. However, vaccine hesitancy is widespread. Survey results on uptake intentions vary and continue to change.
Cheryl Lin, Pikuei Tu, L. Beitsch
semanticscholar   +1 more source

The role of vaccines in combatting antimicrobial resistance

Nature Reviews Microbiology, 2021
The use of antibiotics has enabled the successful treatment of bacterial infections, saving the lives and improving the health of many patients worldwide.
F. Micoli, F. Bagnoli, R. Rappuoli, D. Serruto   +3 more
semanticscholar   +1 more source

Overview of vaccines and vaccination [PDF]

Molecular Biotechnology, 2005
Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and ...
openaire   +4 more sources

HIV: to vaccinate or not to vaccinate? [PDF]

Nature, 1992
"Improbability of effective vaccination against human immunodeficiency virus ...", declares the title of a new paper by Dr Albert Sabin. But three immunologists see flaws in his argument.
Gordon Ada, Arno Müllbacher, Bob Blanden   +2 more
openaire   +2 more sources

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

npj Vaccines, 2022
The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity.
Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn   +7 more
doaj   +1 more source

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

npj Vaccines, 2021
COVID-19 vaccines were developed with an unprecedented pace since the beginning of the pandemic. Several of them have reached market authorization and mass production, leading to their global application on a large scale.
F. Heinz, K. Stiasny
semanticscholar   +1 more source